Ligand Buys Rights To Programs From Selexis

San Diego-based biopharmaceuticals firm Ligand said today that it has acquired a portfolio of potential future milestone and royalty payments for more than 15 biologic development programs from Selexis SA. Financial details of the buy were not disclosed. Selexis SA is based in Geneva, Switzerland, and develops therapeutic protein drugs. Ligand said the move "significantly expands" its portfolio of products.